Sulfated Alginate for Biomedical Applications

Abstract

Alginate (Alg) polymers have received much attention due to the mild conditions required for gel formation and their good bio‐acceptability. However, due to limited interactions with cells, many drugs, and biomolecules, chemically modified alginates are of great interest. Sulfated alginate (S–Alg) is a promising heparin‐mimetic that continues to be investigated both as a drug molecule and as a component of biomaterials. Herein, the S–Alg literature of the past five years (2017–2023) is reviewed. Several methods used to synthesize S–Alg are described, with a focus on new advances in characterization and stereoselectivity. Material fabrication is another focus and spans bulk materials, particles, scaffolds, coatings, and part of multicomponent biomaterials. The new application of S–Alg as an antitumor agent is highlighted together with studies evaluating safety and biodistribution. The high binding affinity of S–Alg for various drugs and heparin‐binding proteins is exploited extensively in biomaterial design to tune the encapsulation and release of these agents and this aspect is covered in detail. Recommondations include publishing key material properties to allow reproducibility, careful selection of appropriate sulfation strategies, the use of cross–linking strategies other than ionic cross–linking for material fabrication, and more detailed toxicity and biodistribution studies to inform future work.